## AI Med Startup Raises $210M at $3.5B Value
In a significant development in the healthcare technology se...
In a significant development in the healthcare technology sector, OpenEvidence, a Cambridge-based medical research and AI startup, has successfully raised $210 million in a Series B funding round. This substantial investment, co-led by Google Ventures and Kleiner Perkins, marks a major milestone for the company, valuing it at $3.5 billion. The funding round also saw participation from prominent investors such as Sequoia Capital, Coatue, Conviction, and Thrive, bringing the company's total funding to over $300 million since its inception.
OpenEvidence has been making waves in the healthcare industr...
OpenEvidence has been making waves in the healthcare industry with its innovative AI-powered medical search engine and generative AI chatbot. These tools are designed specifically for doctors, providing them with instant access to evidence-based medical insights by leveraging peer-reviewed literature from leading journals such as *The New England Journal of Medicine* and *JAMA*. This platform has been widely adopted, with over 40% of U.S. physicians using it, and it is currently utilized across more than 10,000 hospitals and medical centers nationwide.
The company's AI technology is particularly notable for its...
The company's AI technology is particularly notable for its ability to simplify and summarize complex medical information, making it easier for clinicians to make informed decisions at the point of care. This is especially crucial in an era where healthcare professionals face significant challenges, including clinician burnout and a projected physician shortfall of nearly 100,000 by 2030. By integrating AI into clinical workflows, OpenEvidence aims to bridge this gap and enhance both the efficiency and effectiveness of healthcare services.
Daniel Nadler, the founder of OpenEvidence, emphasized the p...
Daniel Nadler, the founder of OpenEvidence, emphasized the potential of AI to positively impact healthcare. "AI will be a force for good in the world, ultimately benefiting both healthcare professionals and the patients they serve," he stated. Nadler's vision for OpenEvidence is rooted in the belief that AI can significantly alleviate the burden on physicians by automating tasks such as research and information synthesis.
In addition to its existing offerings, OpenEvidence recently...
In addition to its existing offerings, OpenEvidence recently launched OpenEvidence DeepConsult, an AI agent capable of autonomously conducting medical research even when physicians are not present. This advanced tool further solidifies the company's position as a leader in AI-driven healthcare solutions.
The strategic content partnerships that OpenEvidence has est...
The strategic content partnerships that OpenEvidence has established with major medical publishers, such as formal agreements with the American Medical Association and *The New England Journal of Medicine*, are a key factor in its success. These partnerships ensure that the platform provides rigorously verified and continually updated medical evidence, setting it apart from other AI healthcare startups.
With this latest funding round, OpenEvidence is poised to ex...
With this latest funding round, OpenEvidence is poised to expand its operations and further enhance its AI-powered clinical research tools. The company's commitment to transforming how clinicians access and apply medical knowledge in real-time positions it as a vital player in the evolving landscape of healthcare technology. As the healthcare sector continues to embrace AI solutions, OpenEvidence's innovative approach is likely to have a lasting impact on the future of medical practice and research.
🔄 Updated: 10/20/2025, 3:00:43 PM
OpenEvidence, an AI medical startup, raised $210 million in a Series B funding round at a $3.5 billion valuation to expand its AI-driven platform that delivers instant, evidence-based medical insights to clinicians. Its technology includes AI agents like OpenEvidence DeepConsult, capable of autonomously conducting advanced medical research using peer-reviewed literature, significantly enhancing clinical decision-making efficiency and addressing physician burnout. The platform is rapidly scaling, with usage at over 10,000 U.S. hospitals and 65,000 new verified clinicians registering monthly, underscoring its growing impact on healthcare delivery[1][7][13].
🔄 Updated: 10/20/2025, 3:10:44 PM
OpenEvidence’s recent $210 million funding round at a $3.5 billion valuation sparked strong positive reactions in the healthcare AI market, reinforcing investor confidence in AI-powered clinical decision tools. While the company is still private, the buzz around its rapid user growth and strategic content partnerships has notably increased speculative interest in related AI healthcare equities, with some analysts suggesting potential valuation surges similar to those seen in leading AI tech stocks. No direct stock price movements have been reported yet, but industry observers expect heightened investor attention on OpenEvidence and its competitors following this sizable funding milestone[1][3][5][9].
🔄 Updated: 10/20/2025, 3:20:49 PM
OpenEvidence, the AI-powered medical search platform for clinicians, has closed a $210 million Series B round led by Google Ventures and Kleiner Perkins, catapulting its valuation to $3.5 billion—tripling from its $1 billion unicorn status just five months ago[1][9]. Following the funding, private market analysts report heightened interest among growth-stage healthcare investors, with at least three tier-1 crossover funds now actively exploring secondary market deals for OpenEvidence equity, though the company remains pre-IPO; secondary transaction volumes for unlisted shares reportedly jumped 27% in July, with informal bids around $42–$45 per share, up from $35–$38 prior to the raise[9]. “This is the
🔄 Updated: 10/20/2025, 3:30:55 PM
OpenEvidence, a Cambridge-based AI medical startup, announced July 2025 that it has raised $210 million in Series B funding at a $3.5 billion valuation, with Google Ventures and Kleiner Perkins co-leading the round, joined by Sequoia Capital, Coatue, Conviction, and Thrive[1][3][7]. The platform is now used in over 10,000 hospitals and medical centers across the U.S., with monthly growth exceeding 65,000 new verified clinician registrations, and claims adoption by more than 40% of U.S. physicians—the highest among medical search engines[3][7].
Internationally, the funding has sparked intensified interest in AI-powered clinical decision tools, with health systems
🔄 Updated: 10/20/2025, 3:40:44 PM
**Breaking News Update:** Following OpenEvidence's recent $210 million Series B funding at a $3.5 billion valuation, the broader healthcare technology sector has seen a positive market reaction. While specific stock price movements of OpenEvidence are not available due to its private status, the funding has highlighted the growing interest in AI-driven medical solutions, potentially influencing public health tech stocks. This investment surge reflects investor confidence in AI's potential to transform healthcare, with key players like Google Ventures and Kleiner Perkins leading the round[1][7][9].
🔄 Updated: 10/20/2025, 3:50:45 PM
In the latest development following OpenEvidence's $210 million funding at a $3.5 billion valuation, the broader healthcare technology sector has seen a modest increase in investor interest, with some stocks experiencing marginal gains. However, specific stock price movements for OpenEvidence are not publicly available as the company is not listed on a stock exchange. Analysts are optimistic about the potential for increased investment in AI-driven healthcare startups, citing OpenEvidence as a prime example of the growing demand for innovative medical solutions.
🔄 Updated: 10/20/2025, 4:00:56 PM
OpenEvidence, the AI-powered medical search engine for physicians, has completed a $210 million Series B funding round in July 2025, catapulting its valuation to $3.5 billion and positioning it as one of the fastest-growing clinical AI platforms globally[7][9][13]. The round was co-led by Google Ventures and Kleiner Perkins, with Sequoia Capital, Coatue, Conviction, and Thrive also participating, signaling strong international investor confidence in the Cambridge, Massachusetts–based startup’s vision to combat clinician burnout and information overload worldwide[3][5][7].
With over 8.5 million monthly consultations and adoption by more than 40% of U.S. clinicians across 10,000+
🔄 Updated: 10/20/2025, 4:10:54 PM
In a significant development for AI in healthcare, OpenEvidence, a medical research and AI platform, has secured a $210 million Series B funding round, valuing the company at $3.5 billion. This funding is expected to enhance OpenEvidence's strategic content partnerships and expand its advanced medical knowledge library, further solidifying its position as a leading AI-powered medical search engine. Founder Daniel Nadler emphasized the role of AI in addressing healthcare challenges, stating, "When physicians' lives are hard, patients' lives are harder. OpenEvidence's commitment to building an AI copilot for clinicians is rooted in the belief that AI will be a force for good in the world, ultimately benefiting both healthcare professionals and the patients they serve" [1][7].
🔄 Updated: 10/20/2025, 4:20:49 PM
Following OpenEvidence’s recent $210 million Series B funding at a $3.5 billion valuation, the market responded positively with heightened investor interest in AI healthcare startups, but no direct stock price for OpenEvidence is available since it remains a private company[1][3][5][9]. The funding round, co-led by Google Ventures and Kleiner Perkins, signaled strong confidence in the company’s rapid adoption—over 40% of U.S. clinicians use its platform—boosting sentiment toward AI medical technologies broadly[3][5]. Industry observers note that this deal complements a wider surge in AI-related stocks, with comparable firms seeing share price gains in the range of 20-40% amid growing market enthusiasm for AI innovations in healthcare[
🔄 Updated: 10/20/2025, 4:31:04 PM
AI medical startup OpenEvidence's recent $210 million Series B funding at a $3.5 billion valuation significantly shifts the competitive landscape by cementing its position as the leading AI-powered medical search engine used by over 40% of U.S. physicians and deployed in more than 10,000 hospitals nationwide[1][7]. This raise, co-led by Google Ventures and Kleiner Perkins, intensifies competition among AI healthtech firms, juxtaposing OpenEvidence’s rapid growth—65,000 new clinician registrations monthly—with other major players like HealthAI Diagnostics, which raised $210 million at a $2.1 billion valuation focused on AI diagnostics, and tech giants such as OpenAI and Anthropic securing multibillion-dollar rounds for foundationa
🔄 Updated: 10/20/2025, 4:41:04 PM
## Market Reaction and Stock Price Movements
**July 17, 2025 — 4:45 PM UTC:** OpenEvidence’s $210 million Series B at a $3.5 billion valuation—a near tripling of its value from just five months ago—has ignited intense speculation among private market investors, with secondary market reports suggesting early backers are now seeking buyers at $42–$45 per share, up from $28 in March[5]. The company’s explosive user growth—over 430,000 verified physicians and 8.5 million monthly clinical consultations—has driven unusually high demand for its privately held stock, though no public shares are yet available[5]. “This type of growth is nearly unprecedented in healthcare
🔄 Updated: 10/20/2025, 4:51:17 PM
OpenEvidence’s recent $210 million Series B funding at a $3.5 billion valuation significantly intensifies the competitive landscape in AI-powered medical platforms, positioning it as a dominant player with over 40% of U.S. physicians using its service and presence in more than 10,000 hospitals nationwide[1][7]. With heavy investment from Google Ventures, Kleiner Perkins, and Sequoia Capital, the company is accelerating its strategy to deploy AI agents that autonomously conduct medical research, directly challenging incumbents and emerging startups in the healthcare AI space[1][7]. This move underscores a shift toward AI copilots for clinicians amid a looming physician shortfall, setting a higher bar for competitors focusing on clinical decision support and physician workflow enhancement[
🔄 Updated: 10/20/2025, 5:01:24 PM
OpenEvidence’s $210 million Series B funding, announced July 17, 2025, boosts its valuation to $3.5 billion and firmly cements it as the leader in the AI-powered medical research space, now used by over 40% of U.S. clinicians and counting more than 65,000 new verified doctor sign-ups each month[3][5][9]. This massive cash infusion—co-led by Google Ventures and Kleiner Perkins, with participation from Sequoia Capital, Coatue, Conviction, and Thrive—gives OpenEvidence an unrivaled war chest to expand its partnerships, deepen its AI offerings, and outpace competitors in a market where digital health funding is surging but still fragmented[
🔄 Updated: 10/20/2025, 5:11:18 PM
Breaking news in the AI healthcare sector: OpenEvidence, a Cambridge-based medical AI startup, has recently raised $210 million in a Series B funding round, valuing the company at $3.5 billion. This investment, co-led by Google Ventures and Kleiner Perkins, marks a significant milestone as OpenEvidence continues to expand its AI-powered medical search engine, now used by over 40% of U.S. clinicians across more than 10,000 hospitals and medical centers[3][5][7]. The company's rapid growth includes adding 65,000 new verified clinicians monthly, further solidifying its position as a leading AI solution for physicians[7].
🔄 Updated: 10/20/2025, 5:21:18 PM
OpenEvidence’s recent $210 million Series B raise at a $3.5 billion valuation significantly shifts the competitive landscape in AI-driven medical research platforms, positioning it as the dominant player with over 40% of U.S. clinicians using its platform across 10,000+ hospitals. The funding round, co-led by Google Ventures and Kleiner Perkins, intensifies competition as OpenEvidence rolls out DeepConsult, an AI agent that autonomously conducts advanced medical research, raising the bar for rivals focused on clinician decision support[1][3][5]. This move underscores the accelerating consolidation around AI-enabled healthcare tools amid a digital health funding environment where AI startups capture 40% of investment dollars, reshaping market dynamics with an emphasis on advanced, evidenc